Reference Data
## Business segments and major products

<table>
<thead>
<tr>
<th>Segments</th>
<th>Description</th>
<th>Major products</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imaging Products Business</strong></td>
<td>Digital camera-interchangeable lens type</td>
<td><a href="#">NIKKOR Z 135mm f/1.8 S Plena</a></td>
</tr>
<tr>
<td></td>
<td>Interchangeable lens</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Compact DSC</td>
<td></td>
</tr>
<tr>
<td><strong>Precise Equipment Business</strong></td>
<td>FPD lithography system</td>
<td><a href="#">NSR-S635E</a></td>
</tr>
<tr>
<td></td>
<td>Semiconductor lithography system</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alignment station</td>
<td><a href="#">Litho Booster</a></td>
</tr>
<tr>
<td></td>
<td>Measuring &amp; inspection system</td>
<td><a href="#">ARF Immersion Scanner</a></td>
</tr>
<tr>
<td><strong>Healthcare Business</strong></td>
<td>Biological microscope</td>
<td><a href="#">Ultra-Widefield Retinal Diagnostic Imaging System with Integrated UWF</a></td>
</tr>
<tr>
<td></td>
<td>Retinal diagnostic imaging system</td>
<td>Source OCT (Silverstone)</td>
</tr>
<tr>
<td></td>
<td>Contract Cell Manufacturing business</td>
<td></td>
</tr>
<tr>
<td><strong>Components Business</strong></td>
<td>EUV related component</td>
<td><a href="#">Photomask Substrate for FPD</a></td>
</tr>
<tr>
<td></td>
<td>Optical parts, Optical components</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Encoders and Actuators</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Photomask substrate for FPD</td>
<td></td>
</tr>
<tr>
<td><strong>Digital Manufacturing Business</strong></td>
<td>Metal 3D printer</td>
<td><a href="#">Laser Radar Measuring System</a></td>
</tr>
<tr>
<td></td>
<td>Optical processing machine</td>
<td><a href="#">APDIS Series</a></td>
</tr>
<tr>
<td></td>
<td>Contract material processing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Measuring instrument</td>
<td></td>
</tr>
<tr>
<td></td>
<td>X-ray system</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Industrial microscopy</td>
<td></td>
</tr>
</tbody>
</table>
Forecast for the year ending March 31, 2024: Financial Highlights

<table>
<thead>
<tr>
<th>Billions of Yen</th>
<th>FY2021/3</th>
<th>FY2022/3</th>
<th>FY2023/3</th>
<th>FY2024/3 Forecast</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Full Year</td>
<td>Full Year</td>
<td>1H</td>
<td>2H</td>
</tr>
<tr>
<td>Revenue</td>
<td>451.2</td>
<td>539.6</td>
<td>288.3</td>
<td>339.8</td>
</tr>
<tr>
<td>Operating profit</td>
<td>-56.2</td>
<td>49.9</td>
<td>24.4</td>
<td>30.5</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>-12.5%</td>
<td>9.3%</td>
<td>8.5%</td>
<td>9.0%</td>
</tr>
<tr>
<td>Profit before tax</td>
<td>-45.3</td>
<td>57.0</td>
<td>26.0</td>
<td>31.0</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>-10.0%</td>
<td>10.6%</td>
<td>9.0%</td>
<td>9.1%</td>
</tr>
<tr>
<td>Profit attributable to owners of parent</td>
<td>-34.4</td>
<td>42.6</td>
<td>18.8</td>
<td>26.1</td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>-7.6%</td>
<td>7.9%</td>
<td>6.5%</td>
<td>7.7%</td>
</tr>
<tr>
<td>ROE</td>
<td>-6.4%</td>
<td>7.5%</td>
<td>7.4%</td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>-¥93.96</td>
<td>¥116.23</td>
<td>¥125.46</td>
<td>¥77.96</td>
</tr>
<tr>
<td>Annual Dividends</td>
<td>¥20</td>
<td>¥40</td>
<td>¥45</td>
<td>¥50</td>
</tr>
<tr>
<td>FCF</td>
<td>22.9</td>
<td>30.9</td>
<td>-112.1</td>
<td></td>
</tr>
<tr>
<td>Exchange Rate: US$</td>
<td>¥106</td>
<td>¥112</td>
<td>¥134</td>
<td>¥135</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>¥141</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>¥140</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>¥141</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>¥153</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>¥150</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>¥152</td>
</tr>
</tbody>
</table>

Note: The number of issued shares assumed for EPS forecast calculation: approx. 346.3M shares
Forecast for the year ending March 31, 2024: Financial Highlights (Changes from Previous Forecast)

<table>
<thead>
<tr>
<th></th>
<th>Revenue</th>
<th>Operating profit</th>
<th>Profit before tax</th>
<th>Profit attributable to owners of parent</th>
<th>ROE</th>
<th>EPS</th>
<th>Annual Dividends</th>
<th>Exchange Rate: US$</th>
<th>Exchange Rate: EURO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Aug. 8) (A)</td>
<td>(Nov. 9) (B)</td>
<td>(B)-(A)</td>
<td>(B)-(A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1H</td>
<td>325.0</td>
<td>331.2</td>
<td>+6.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2H</td>
<td>345.0</td>
<td>358.8</td>
<td>+13.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full Year</td>
<td>670.0</td>
<td>690.0</td>
<td>+20.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>4.6%</td>
<td>4.1%</td>
<td>-0.5P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.1%</td>
<td>5.7%</td>
<td>-2.4P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.4%</td>
<td>4.9%</td>
<td>-1.5P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1H</td>
<td>15.0</td>
<td>13.6</td>
<td>-1.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2H</td>
<td>28.0</td>
<td>20.4</td>
<td>-7.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full Year</td>
<td>43.0</td>
<td>34.0</td>
<td>-9.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>4.6%</td>
<td>4.1%</td>
<td>-0.5P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.4%</td>
<td>5.7%</td>
<td>-2.4P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.9%</td>
<td>4.9%</td>
<td>-1.5P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1H</td>
<td>17.0</td>
<td>15.2</td>
<td>-1.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2H</td>
<td>29.0</td>
<td>21.8</td>
<td>-7.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full Year</td>
<td>46.0</td>
<td>37.0</td>
<td>-9.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>5.2%</td>
<td>4.6%</td>
<td>-0.6P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.4%</td>
<td>6.1%</td>
<td>-2.3P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.9%</td>
<td>5.4%</td>
<td>-1.5P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1H</td>
<td>12.0</td>
<td>9.8</td>
<td>-2.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2H</td>
<td>23.0</td>
<td>17.2</td>
<td>-5.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full Year</td>
<td>35.0</td>
<td>27.0</td>
<td>-8.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% vs Revenue</td>
<td>3.7%</td>
<td>3.0%</td>
<td>-0.7P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.7%</td>
<td>4.8%</td>
<td>-1.9P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5.2%</td>
<td>3.9%</td>
<td>-1.3P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROE</td>
<td>5.6%</td>
<td>4.2%</td>
<td>-1.4P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS</td>
<td>¥101.09</td>
<td>¥77.96</td>
<td>-¥23.13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual Dividends</td>
<td>¥50</td>
<td>¥50</td>
<td>±¥0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exchange Rate: US$</td>
<td>¥134</td>
<td>¥131</td>
<td>¥132</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EURO</td>
<td>¥147</td>
<td>¥145</td>
<td>¥146</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>¥141</td>
<td>¥140</td>
<td>¥141</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>¥153</td>
<td>¥150</td>
<td>¥152</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.2M shares for previous forecast (Aug. 8) and approx. 346.3M shares for new forecast (Nov. 9)
Forecast for the year ending March 31, 2024:
Forecast by Segment

<table>
<thead>
<tr>
<th>Billions of Yen</th>
<th>FY2023/3</th>
<th>FY2024/3 Forecast</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1H</td>
<td>2H</td>
</tr>
<tr>
<td><strong>Imaging Products Business</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>114.5</td>
<td>112.6</td>
</tr>
<tr>
<td>Operating profit</td>
<td>22.2</td>
<td>20.0</td>
</tr>
<tr>
<td><strong>Precision Equipment Business</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>83.3</td>
<td>119.9</td>
</tr>
<tr>
<td>Operating profit</td>
<td>6.2</td>
<td>18.3</td>
</tr>
<tr>
<td><strong>Healthcare Business</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>46.6</td>
<td>52.7</td>
</tr>
<tr>
<td>Operating profit</td>
<td>3.6</td>
<td>7.9</td>
</tr>
<tr>
<td><strong>Components Business</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>25.6</td>
<td>27.4</td>
</tr>
<tr>
<td>Operating profit</td>
<td>11.3</td>
<td>10.7</td>
</tr>
<tr>
<td><strong>Digital Manufacturing Business</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>16.2</td>
<td>25.8</td>
</tr>
<tr>
<td>Operating profit</td>
<td>-2.8</td>
<td>-7.3</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>1.7</td>
<td>1.5</td>
</tr>
<tr>
<td>Operating profit</td>
<td>1.0</td>
<td>1.6</td>
</tr>
<tr>
<td><strong>Corporate expenses, etc.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating profit</td>
<td>-17.2</td>
<td>-20.8</td>
</tr>
<tr>
<td>Broken out: Expense related to investment in growth</td>
<td>-10.1</td>
<td>-11.6</td>
</tr>
<tr>
<td>Broken out: Expense for administration department</td>
<td>-5.8</td>
<td>-7.7</td>
</tr>
<tr>
<td>Broken out: Elimination of intersegment transactions</td>
<td>-1.2</td>
<td>-1.5</td>
</tr>
<tr>
<td><strong>Consolidated</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>288.3</td>
<td>339.8</td>
</tr>
<tr>
<td>Operating profit</td>
<td>24.4</td>
<td>30.5</td>
</tr>
</tbody>
</table>

Note: FY2023/3 results have been re-stated to reflect segmentation changes.
“Expense related to investment in growth” is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.
“Expense for administration department” is the general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments.
**Forecast for the year ending March 31, 2024:**

Forecast by Segment (Changes from Previous Forecast)

<table>
<thead>
<tr>
<th>Segment</th>
<th>Previous Forecast (Aug. 8) (A)</th>
<th>New Forecast (Nov. 9) (B)</th>
<th>Change (B)-(A)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1H</td>
<td>2H</td>
<td>Full Year</td>
</tr>
<tr>
<td><strong>Imaging Products Business</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>135.0</td>
<td>115.0</td>
<td>250.0</td>
</tr>
<tr>
<td>Operating profit</td>
<td>25.0</td>
<td>16.0</td>
<td>41.0</td>
</tr>
<tr>
<td><strong>Precision Equipment Business</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>95.0</td>
<td>110.0</td>
<td>205.0</td>
</tr>
<tr>
<td>Operating profit</td>
<td>3.2</td>
<td>4.8</td>
<td>8.0</td>
</tr>
<tr>
<td><strong>Healthcare Business</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>45.0</td>
<td>50.0</td>
<td>95.0</td>
</tr>
<tr>
<td>Operating profit</td>
<td>2.7</td>
<td>6.8</td>
<td>9.5</td>
</tr>
<tr>
<td><strong>Components Business</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>20.0</td>
<td>33.0</td>
<td>53.0</td>
</tr>
<tr>
<td>Operating profit</td>
<td>6.0</td>
<td>14.0</td>
<td>20.0</td>
</tr>
<tr>
<td><strong>Digital Manufacturing Business</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>28.0</td>
<td>36.0</td>
<td>64.0</td>
</tr>
<tr>
<td>Operating profit</td>
<td>-6.0</td>
<td>-3.0</td>
<td>-9.0</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>2.0</td>
<td>1.0</td>
<td>3.0</td>
</tr>
<tr>
<td>Operating profit</td>
<td>1.0</td>
<td>3.0</td>
<td>4.0</td>
</tr>
<tr>
<td><strong>Corporate expenses, etc.</strong></td>
<td>-17.0</td>
<td>-19.0</td>
<td>-36.0</td>
</tr>
<tr>
<td>Broken out: Expense related to investment in growth</td>
<td>-10.0</td>
<td>-10.0</td>
<td>-20.0</td>
</tr>
<tr>
<td>Broken out: Expense for administration department</td>
<td>-7.0</td>
<td>-9.0</td>
<td>-16.0</td>
</tr>
<tr>
<td>Broken out: Elimination of intersegment transactions</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Consolidated</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>325.0</td>
<td>345.0</td>
<td>670.0</td>
</tr>
<tr>
<td>Operating profit</td>
<td>15.0</td>
<td>28.0</td>
<td>43.0</td>
</tr>
</tbody>
</table>

Note: “Expense related to investment in growth” is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.

“Expense for administration department” is the general administrative expenses for head office functions, and corporate P/L non- attributable to any reportable segments.
**Q2 of the year ending March 31, 2024: Quarterly Performance by Segment**

<table>
<thead>
<tr>
<th></th>
<th>FY2023/3</th>
<th></th>
<th></th>
<th></th>
<th>FY2024/3</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
<td>Q2</td>
</tr>
<tr>
<td>Imaging Products Business</td>
<td>Revenue</td>
<td>61.2</td>
<td>53.3</td>
<td>69.9</td>
<td>42.7</td>
<td>74.4</td>
<td>63.2</td>
</tr>
<tr>
<td></td>
<td>Operating profit</td>
<td>13.6</td>
<td>8.6</td>
<td>19.0</td>
<td>1.0</td>
<td>15.3</td>
<td>9.9</td>
</tr>
<tr>
<td>Precision Equipment Business</td>
<td>Revenue</td>
<td>41.4</td>
<td>41.9</td>
<td>50.2</td>
<td>69.7</td>
<td>37.3</td>
<td>58.7</td>
</tr>
<tr>
<td></td>
<td>Operating profit</td>
<td>3.9</td>
<td>2.3</td>
<td>8.1</td>
<td>10.2</td>
<td>-3.6</td>
<td>6.8</td>
</tr>
<tr>
<td>Healthcare Business</td>
<td>Revenue</td>
<td>21.7</td>
<td>24.9</td>
<td>25.5</td>
<td>27.2</td>
<td>25.2</td>
<td>26.0</td>
</tr>
<tr>
<td></td>
<td>Operating profit</td>
<td>0.8</td>
<td>2.8</td>
<td>3.6</td>
<td>4.3</td>
<td>1.8</td>
<td>0.9</td>
</tr>
<tr>
<td>Components Business</td>
<td>Revenue</td>
<td>12.8</td>
<td>12.8</td>
<td>11.8</td>
<td>15.6</td>
<td>8.4</td>
<td>10.3</td>
</tr>
<tr>
<td></td>
<td>Operating profit</td>
<td>5.9</td>
<td>5.4</td>
<td>4.4</td>
<td>6.3</td>
<td>2.4</td>
<td>3.5</td>
</tr>
<tr>
<td>Digital Manufacturing Business</td>
<td>Revenue</td>
<td>7.4</td>
<td>8.8</td>
<td>9.8</td>
<td>16.0</td>
<td>11.9</td>
<td>14.2</td>
</tr>
<tr>
<td></td>
<td>Operating profit</td>
<td>-0.9</td>
<td>-1.9</td>
<td>-1.0</td>
<td>-6.3</td>
<td>-4.7</td>
<td>-4.8</td>
</tr>
<tr>
<td>Others</td>
<td>Revenue</td>
<td>0.9</td>
<td>0.8</td>
<td>0.8</td>
<td>0.7</td>
<td>0.6</td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td>Operating profit</td>
<td>0.7</td>
<td>0.3</td>
<td>0.0</td>
<td>1.6</td>
<td>-0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Corporate expenses, etc.</td>
<td>Operating profit</td>
<td>-8.7</td>
<td>-8.5</td>
<td>-8.1</td>
<td>-12.7</td>
<td>-7.8</td>
<td>-6.3</td>
</tr>
<tr>
<td>Broken out: Expense related to investment in growth</td>
<td>-5.0</td>
<td>-5.1</td>
<td>-5.6</td>
<td>-6.0</td>
<td>-5.1</td>
<td>-5.1</td>
<td></td>
</tr>
<tr>
<td>Broken out: Expense for administration department</td>
<td>-2.7</td>
<td>-3.1</td>
<td>-3.3</td>
<td>-4.4</td>
<td>-3.4</td>
<td>-3.4</td>
<td></td>
</tr>
<tr>
<td>Broken out: Elimination of intersegment transactions</td>
<td>-0.9</td>
<td>-0.3</td>
<td>0.8</td>
<td>-2.3</td>
<td>0.7</td>
<td>2.2</td>
<td></td>
</tr>
<tr>
<td>Consolidated</td>
<td>Revenue</td>
<td>145.6</td>
<td>142.7</td>
<td>167.7</td>
<td>172.1</td>
<td>158.1</td>
<td>173.1</td>
</tr>
<tr>
<td></td>
<td>Operating profit</td>
<td>15.3</td>
<td>9.1</td>
<td>26.2</td>
<td>4.3</td>
<td>3.2</td>
<td>10.4</td>
</tr>
</tbody>
</table>

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

“Expense related to investment in growth” is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.

“Expense for administration department” is the general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments.
### Financial Position

<table>
<thead>
<tr>
<th></th>
<th>22/9</th>
<th>23/3</th>
<th>23/9</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSET</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash &amp; cash equivalents</td>
<td>345.4</td>
<td>211.3</td>
<td>176.3</td>
</tr>
<tr>
<td>Trade &amp; other receivables</td>
<td>94.0</td>
<td>114.2</td>
<td>134.7</td>
</tr>
<tr>
<td>Inventories</td>
<td>279.9</td>
<td>277.2</td>
<td>301.0</td>
</tr>
<tr>
<td>Other current financial /current assets</td>
<td>19.6</td>
<td>15.0</td>
<td>33.9</td>
</tr>
<tr>
<td>Non-current assets</td>
<td>355.3</td>
<td>432.3</td>
<td>452.7</td>
</tr>
<tr>
<td><strong>Non-current assets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Equity ratio</strong></th>
<th>22/9</th>
<th>23/3</th>
<th>23/9</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>57.0%</td>
<td>58.6%</td>
<td>59.2%</td>
</tr>
</tbody>
</table>

**Note:** Equity ratio is the ratio of equity attributable to owners of parent to total assets. Cash and cash equivalents excludes time deposits with maturities of three months or more.
Capital Expenditures, Depreciation & Amortization, and Inventories

**CAPITAL EXPENDITURES, DEPRECIATION & AMORTIZATION**

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Capital Expenditures</th>
<th>Depreciation &amp; Amortization</th>
</tr>
</thead>
<tbody>
<tr>
<td>20/3</td>
<td>28.7</td>
<td>34.1</td>
</tr>
<tr>
<td>21/3</td>
<td>30.5</td>
<td>30.2</td>
</tr>
<tr>
<td>22/3</td>
<td>42.1</td>
<td>42.1</td>
</tr>
<tr>
<td>23/3</td>
<td>29.0</td>
<td>29.0</td>
</tr>
<tr>
<td>24/3</td>
<td>70.0</td>
<td>35.0</td>
</tr>
</tbody>
</table>

**BREAKDOWN OF INVENTORIES**

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Capital Expenditures</th>
<th>Depreciation &amp; Amortization</th>
</tr>
</thead>
<tbody>
<tr>
<td>21/9</td>
<td>222.6</td>
<td>28.4</td>
</tr>
<tr>
<td>22/3</td>
<td>238.9</td>
<td>29.9</td>
</tr>
<tr>
<td>22/9</td>
<td>279.9</td>
<td>26.9</td>
</tr>
<tr>
<td>23/9</td>
<td>301.0</td>
<td>29.2</td>
</tr>
<tr>
<td>23/3</td>
<td>17.7</td>
<td>9.7</td>
</tr>
<tr>
<td>23/9</td>
<td>21.0</td>
<td>19.0</td>
</tr>
<tr>
<td>23/3</td>
<td>24.5</td>
<td>21.3</td>
</tr>
<tr>
<td>23/9</td>
<td>26.9</td>
<td>24.5</td>
</tr>
<tr>
<td>23/3</td>
<td>11.2</td>
<td>24.5</td>
</tr>
<tr>
<td>23/9</td>
<td>27.3</td>
<td>14.3</td>
</tr>
<tr>
<td>23/3</td>
<td>11.6</td>
<td>12.1</td>
</tr>
<tr>
<td>23/9</td>
<td>11.6</td>
<td>16.9</td>
</tr>
<tr>
<td>23/3</td>
<td>21.3</td>
<td>24.5</td>
</tr>
<tr>
<td>23/9</td>
<td>14.3</td>
<td>24.5</td>
</tr>
</tbody>
</table>

Note: Capital expenditures include right-of-use assets. Depreciation & amortization includes right-of-use assets, depreciation of property, plant and equipment and amortization of intangible assets obtained by business combination. Inventories of FY2023/3 results have been re-stated to reflect segmentation changes.
1H of the year ending March 31, 2024: Revenue Breakdown

BY SEGMENT

<table>
<thead>
<tr>
<th>Segment</th>
<th>FY2023/3 1H (B)</th>
<th>FY2024/3 1H (B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digital Manufacturing</td>
<td>16.2</td>
<td>26.1</td>
</tr>
<tr>
<td>Components</td>
<td>25.6</td>
<td>46.6</td>
</tr>
<tr>
<td>Healthcare</td>
<td>51.2</td>
<td>96.0</td>
</tr>
<tr>
<td>Imaging Products</td>
<td>164.5</td>
<td>137.6</td>
</tr>
<tr>
<td>Others</td>
<td>1.7</td>
<td>1.4</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>331.2B</strong></td>
<td><strong>331.2B</strong></td>
</tr>
</tbody>
</table>

BY REGION

<table>
<thead>
<tr>
<th>Region</th>
<th>FY2023/3 1H (B)</th>
<th>FY2024/3 1H (B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Japan</td>
<td>50.8</td>
<td>67.3</td>
</tr>
<tr>
<td>China</td>
<td>55.6</td>
<td>54.0</td>
</tr>
<tr>
<td>United States</td>
<td>82.1</td>
<td>78.7</td>
</tr>
<tr>
<td>Europe</td>
<td>45.3</td>
<td>54.0</td>
</tr>
<tr>
<td>Others</td>
<td>1.7</td>
<td>1.4</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>288.3B</strong></td>
<td><strong>331.2B</strong></td>
</tr>
</tbody>
</table>

Note: The outside and inside circles show the breakdown of FY2024/3 1H revenue of ¥331.2B and FY2023/3 1H revenue of ¥288.3B, respectively. FY2023/3 results have been re-stated to reflect segmentation changes.
Forecast for the year ending March 31, 2024: R&D Expenditures

R&D EXPENDITURES

Forecast for the year ending March 31, 2024:

R&D EXPENDITURES BREAKDOWN

Billions of Yen

- **Corporation (Undistributed)**: 19.0
- **Imaging Products**: 29%
- **Precision Equipment**: 26%
- **Components**: 23%
- **Digital Manufacturing**: 19%
- **Healthcare**: 10%
- **Other**

Note: R&D expenditures includes capitalization of some development expenditures.
Due to segment revision from FY2024/3, the financial figures for FY2023/3 are displayed according to the reorganized display.
Cash Flow History

Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents
Imaging Products Business: Sales Units

SALES IN UNITS BY PRODUCT CATEGORY

- DCIL (Digital Camera - Interchangeable Lens Type)
- Interchangeable Lens

1,500K Units
Forecast for the year ending March 31, 2024: Precision Equipment Business Sales Units

**FPD LITHOGRAPHY SYSTEMS SALES BY GENERATION**

<table>
<thead>
<tr>
<th>Generation</th>
<th>20/3 Actual</th>
<th>21/3 Actual</th>
<th>22/3 Actual</th>
<th>23/3 Actual</th>
<th>24/3 Forecast (Aug. 8)</th>
<th>24/3 Actual</th>
<th>G7/8</th>
<th>G10.5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>18</td>
<td>14</td>
<td>30</td>
<td>17</td>
<td>12</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>4</td>
<td>11</td>
<td>10</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)**

<table>
<thead>
<tr>
<th>Technology</th>
<th>20/3 Actual</th>
<th>21/3 Actual</th>
<th>22/3 Actual</th>
<th>23/3 Actual</th>
<th>24/3 Forecast (Aug. 8)</th>
<th>24/3 Forecast (Nov. 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ArF immersion</td>
<td>49</td>
<td>14</td>
<td>34</td>
<td>35</td>
<td>45</td>
<td>48</td>
</tr>
<tr>
<td>ArF</td>
<td>14</td>
<td>6</td>
<td>7</td>
<td>3</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>KrF</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>i-line, etc.</td>
<td>18</td>
<td>17</td>
<td>24</td>
<td>27</td>
<td>23</td>
<td>23</td>
</tr>
</tbody>
</table>

Note: “i-line, etc.” part in numbers of semiconductor lithography systems sales include sales numbers of the “Mini Step & Repeat Exposure System”.

The unit sales of new semiconductor lithography systems are 38 units in FY2020/3, 23 units in FY2021/3, 17 units in FY2022/3, 27 units in FY2023/3, and 30 units (forecast) in FY2024/3.
# Precision Equipment Business: Sales Units

## FPD Lithography Systems Sales in Units by Generation

<table>
<thead>
<tr>
<th>Quarter</th>
<th>G5/6</th>
<th>G7/8</th>
<th>G10.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023 Q1</td>
<td>9</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>2023 Q2</td>
<td>4</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>2023 Q3</td>
<td>6</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>2023 Q4</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2024 Q1</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2024 Q2</td>
<td>12</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>2024 Q3</td>
<td>3</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>2024 Q4</td>
<td>7</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2025 Q1</td>
<td>17</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>2025 Q2</td>
<td>13</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>2025 Q3</td>
<td>7</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2025 Q4</td>
<td>9</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>2026 Q1</td>
<td>7</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>2026 Q2</td>
<td>6</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>2026 Q3</td>
<td>3</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>2026 Q4</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>2027 Q1</td>
<td>10</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>2027 Q2</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

30 Units
Precision Equipment Business: Sales Units

**SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES IN UNITS BY TECHNOLOGY (INCL. REFURBISHED)**

Note: “i-line, etc.” part in numbers of semiconductor lithography systems sales include sales numbers of the “Mini Step & Repeat Exposure System”.

---

### Precision Equipment Business: Sales Units

**SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES IN UNITS BY TECHNOLOGY (INCL. REFURBISHED)**

Note: “i-line, etc.” part in numbers of semiconductor lithography systems sales include sales numbers of the “Mini Step & Repeat Exposure System”.

---

**SANITATION SPECIFICATION FOR PRECISION EQUIPMENT BUSINESS:**

- **Sales Units**
  - **In Units by Technology (Incl. Refurbished)**
    - **i-line, etc.**
    - **KrF**
    - **ArF**
    - **ArF Immersion**

---

**Note:** “i-line, etc.” part in numbers of semiconductor lithography systems sales include sales numbers of the “Mini Step & Repeat Exposure System”.

---

**Legend:**
- **i-line, etc.**
- **KrF**
- **ArF**
- **ArF Immersion**
Forecast for the year ending March 31, 2024:
Foreign Exchange Impact

<table>
<thead>
<tr>
<th>Exchange Rate</th>
<th>FY2024/3 Forecast for 2H</th>
<th>Financial Impact from Fluctuation by 1 yen</th>
<th>Revenue 2H</th>
<th>Operating Profit 2H</th>
</tr>
</thead>
<tbody>
<tr>
<td>US $</td>
<td>¥140</td>
<td>Approx. ¥0.8billion</td>
<td>Approx. ¥0.2billion</td>
<td></td>
</tr>
<tr>
<td>EURO</td>
<td>¥150</td>
<td>Approx. ¥0.4billion</td>
<td>Approx. ¥0.1billion</td>
<td></td>
</tr>
</tbody>
</table>

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US$ and Euro.
Revised Business Segments:

<table>
<thead>
<tr>
<th>Old Segment</th>
<th>Business Unit (BU)</th>
<th>New Segment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging Products</td>
<td>Imaging BU</td>
<td>Imaging Products</td>
</tr>
<tr>
<td>Precision Equipment</td>
<td>FPD Lithography BU, Semiconductor Lithography BU</td>
<td>Precision Equipment</td>
</tr>
<tr>
<td>Healthcare</td>
<td>Healthcare BU</td>
<td>Healthcare</td>
</tr>
<tr>
<td>Components</td>
<td>Customized Products BU, Glass BU, Digital Solutions BU</td>
<td>Components</td>
</tr>
<tr>
<td></td>
<td>Optical components, etc., Material processing (incl. Morf3D)</td>
<td></td>
</tr>
<tr>
<td>Industrial Metrology and Others</td>
<td>Industrial Metrology BU, Others</td>
<td>Digital Manufacturing</td>
</tr>
<tr>
<td></td>
<td>Advanced Manufacturing BU, SLM</td>
<td></td>
</tr>
<tr>
<td>Corporate expenses, etc.</td>
<td>Headquarters division of the parent company</td>
<td>Corporate expenses, etc.</td>
</tr>
<tr>
<td></td>
<td>Next Generation Project Division (partly)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Departments and subsidiaries in the Material Processing Business have been consolidated under the Advanced Manufacturing BU and combined with the Industrial Metrology BU to make up the Digital Manufacturing Business segment (aligns with Medium-Term Management Plan business domain).

* From FY2024/3, domestic production subsidiaries under the Precision Equipment Business have been transferred to the Production Division included under the Others segment.
Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.